US drug regulator launches program to share reviews abroad


The agency says foreign regulators can use its assessments when considering medicines for sale. The program began with a tentative approval for the HIV medicine lenacapavir.
The US Food and Drug Administration announced on 17 November 2026, that it had launched a program to share drug review documents with companies for submission to regulators in other countries. The agency says those regulators could use its assessments instead of repeating evaluations, potentially speeding access to medicines.
The Global Reliance Disclosure Program began on 30 October with a tentative approval under the President’s Emergency Plan for AIDS Relief (PEPFAR) for lenacapavir, a medicine used for HIV prevention and treatment. The FDA says patients can otherwise wait months or years for national reviews in places with limited regulatory resources.
The FDA will give eligible companies approval packages with little information removed, including its scientific and regulatory assessments. Companies can share them with foreign regulators, which retain authority over whether a medicine can be sold locally.
For now, the program covers PEPFAR tentative approvals, except products with tentatively approved abbreviated new drug applications. Applicants must request participation within 10 calendar days of approval and confirm that they are submitting the package to a foreign regulator in support of an application to market the medicine.
Dr. Reddy’s Laboratories received tentative FDA approval for the first generic injectable lenacapavir for HIV prevention, health partnership Unitaid says. It says the designation is used for generics while the original medicine remains under patent and allows the US government to procure them.

Unitaid says Gilead granted voluntary licenses to six generic manufacturers, including Dr. Reddy’s, in late 2024. Unitaid, research institute Wits RHI and the Clinton Health Access Initiative supported the company’s development and filing. Dr. Reddy’s combined prevention and treatment in one application, allowing it to use the FDA’s 505(b)(2) pathway, under which the FDA granted priority review.
Unitaid says national approvals and introduction in countries remain steps toward access. Under a partnership agreement, it says the injection will cost $40 per person per year in the 120 low- and middle-income countries covered by Gilead’s license.
Countries need health systems that are ready to deliver new prevention options, providers who are confident in offering them, and communities that are engaged as partners in their introduction and scale-up.
The FDA intends to expand the program in January 2027 to novel drugs and biologics submitted through New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. Biologics are medicines made from living sources. The agency also plans a separate pathway in early 2027 to expedite requests for minimally redacted action packages for medicines already approved or licensed in the United States.
Unitaid expects initial supplies of generic lenacapavir to reach countries by the end of 2026, with broader availability in 2027.
A USC Norman Lear Center and Good Energy study found climate terms in 3.2% of 35,120 scripts from 2021–24, up from 2.8%, using the same keywords as its earlier 2016–20 analysis.
1 min

About 20 Awá living in voluntary isolation approached Guajajara villagers in Brazil on 16 November. Brazil’s Indigenous affairs agency says its teams are monitoring the situation and reviewing information about the group’s health.
2 min

The bill would give the Space Force $54.8 billion, but the Senate proposal still needs a floor vote and the House has not passed its own fiscal 2027 defense appropriations bill.
2 min